NASDAQ:PASG - Passage Bio Stock Price, Forecast & News

Passage Bio's stock was trading at $18.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PASG stock has decreased by 33.6% and is now trading at $12.53. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Passage Bio.

4 brokerages have issued 12 month target prices for Passage Bio's shares. Their forecasts range from $25.00 to $30.00. On average, they expect Passage Bio's share price to reach $27.33 in the next twelve months. This suggests a possible upside of 118.1% from the stock's current price. View analysts' price targets for Passage Bio.

Press coverage about PASG stock has been trending very negative on Saturday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Passage Bio earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news aboutPassage Bio.

Some companies that are related to Passage Bio include Denali Therapeutics (DNLI), Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Regenxbio (RGNX), Editas Medicine (EDIT), Coherus Biosciences (CHRS), I-Mab (BDTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), Beam Therapeutics (BEAM), Adverum Biotechnologies (ADVM) and Sangamo Therapeutics (SGMO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), QUALCOMM (QCOM), Alector (ALEC), Beam Therapeutics (BEAM), Editas Medicine (EDIT), MeiraGTx (MGTX), Moderna (MRNA), Bill.com (RVMD) and Schrodinger (SDGR).

(PASG) raised $126 million in an initial public offering on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Chardan was co-manager.

Passage Bio trades on the NASDAQ under the ticker symbol "PASG."

Passage Bio's quiet period expires on Wednesday, April 8th. Passage Bio had issued 12,000,000 shares in its public offering on February 28th. The total size of the offering was $216,000,000 based on an initial share price of $18.00. During Passage Bio's quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Shares of PASG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PASG stock can currently be purchased for approximately $12.53.

Passage Bio has a market capitalization of $551.32 million. Passage Bio employs 20 workers across the globe. View additional information about Passage Bio.

The official website for Passage Bio is http://www.passagebio.com/.

Passage Bio's mailing address is TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103. The company can be reached via phone at 267-866-0311 or via email at [email protected]